Whalatane
1 month ago
1 min read
SAVE
Legislation pushes for a delay in placing phosphate binders in the ESRD payment bundle
Add topic to email alerts
Key takeaways:
The Kidney Patient Act would delay placement of oral phosphate binders into the dialysis payment bundle.
Binders would be placed in the bundle if an injectable version receives FDA approval.
Congress is reviewing legislation that would delay inclusion of oral phosphate binders into the End-Stage Renal Disease Prospective Payment System bundled payment system.
NNI0324Carter_Graphic_01
CMS currently has plans to include oral binders in the bundle by Jan. 1, 2025, but the Kidney Patient Act (H.R. 5074), sponsored by U.S. Rep. Earl L. โBuddyโ Carter, R-Ga., would amend the American Taxpayer Relief Act of 2012 to delay inclusion of the binders until 2033.
โEnsuing that the pending inclusion of oral-only drugs in the [End-Stage Renal Disease] Prospective Payment System (PPS) bundle meets the needs of the ESRD community is a priority for Kidney Care Partners, so weโre encouraged by the recent activity in the House of Representatives on this policy,โ Mahesh Krishnan, MD, MPH, MBA, FASN, chair of Kidney Care Partners (KCP), told Healio.
โWithout congressional action, this harmful policy would exacerbate the challenges the kidney community already faces, including diminished access to innovative therapies, insufficient reimbursement and limited or nonexistent choice of insurance coverage for patients,โ KCP, a kidney community advocacy group, said in a press release.
According to language in the bill, placement of oral drugs indicated for the โreduction, management or control of the serum phosphate of an individualโ would be delayed until 2033 unless โan intravenous drug indicated for the reduction, management or control of the serum phosphate of an individual has been approved by the [FDA].โ
The General Accounting Office (GAO) released a report last November reviewing plans by CMS to include oral phosphate binders in the PPS by 2025. The report notes that dialysis organizations interviewed by the GAO โexpressed concerns that the modified bundled payment may not fully account for the costs of acquiring, shipping and dispensing phosphate binders.โ
References:
ErnieBilco
2 months ago
1st let me say I have been very bullish on ARDX from the beginning but I now doubt their ability to progress. It seems everything management and the BOD are doing is to enrich themselves not shareholders, just today the BOD directors decided to add almost 14 million shares to their employee benefit plan - THAT'S ALMOST $140,000,000 TO THEMSELVES while the company remains in the red. When such absurd self dealing occurs it is a giant red flag. Additionally, why would they price their new drug at a price that patients and insurance companies will not cover IMO? Seems it is all about the C suite and the hell with the actual shareholders of the company.
I could be wrong but with each passing day and other competing products in the pipelines of other companies the value of ARDX becomes less compelling to me, hell I was calling for $30 a long time ago but now, seeing this absurd compensation package they have dealt themselves I doubt it sees $15 they are just too greedy to be a benefit to shareholders.
Rethinking my position here which is a direct result of how management is handling the company's fiduciary responsibilities.